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Abstract
Autoimmune thyroid diseases (AITD) are common, affecting 2-5% of the general population. Individuals with positive
thyroid peroxidase antibodies (TPOAbs) have an increased risk of autoimmune hypothyroidism (Hashimoto’s thyroiditis), as
well as autoimmune hyperthyroidism (Graves’ disease). As the possible causative genes of TPOAbs and AITD remain largely
unknown, we performed GWAS meta-analyses in 18,297 individuals for TPOAb-positivity (1769 TPOAb-positives and 16,528
TPOAb-negatives) and in 12,353 individuals for TPOAb serum levels, with replication in 8,990 individuals. Significant
associations (P,561028) were detected at TPO-rs11675434, ATXN2-rs653178, and BACH2-rs10944479 for TPOAb-positivity,
and at TPO-rs11675434, MAGI3-rs1230666, and KALRN-rs2010099 for TPOAb levels. Individual and combined effects (genetic
risk scores) of these variants on (subclinical) hypo- and hyperthyroidism, goiter and thyroid cancer were studied. Individuals
with a high genetic risk score had, besides an increased risk of TPOAb-positivity (OR: 2.18, 95% CI 1.68–2.81, P= 8.161028), a
higher risk of increased thyroid-stimulating hormone levels (OR: 1.51, 95% CI 1.26–1.82, P= 2.961026), as well as a decreased
risk of goiter (OR: 0.77, 95% CI 0.66–0.89, P= 6.561024). The MAGI3 and BACH2 variants were associated with an increased
risk of hyperthyroidism, which was replicated in an independent cohort of patients with Graves’ disease (OR: 1.37, 95% CI
1.22–1.54, P= 1.261027 and OR: 1.25, 95% CI 1.12–1.39, P= 6.261025). The MAGI3 variant was also associated with an
increased risk of hypothyroidism (OR: 1.57, 95% CI 1.18–2.10, P= 1.961023). This first GWAS meta-analysis for TPOAbs
identified five newly associated loci, three of which were also associated with clinical thyroid disease. With these markers we
identified a large subgroup in the general population with a substantially increased risk of TPOAbs. The results provide
insight into why individuals with thyroid autoimmunity do or do not eventually develop thyroid disease, and these markers
may therefore predict which TPOAb-positives are particularly at risk of developing clinical thyroid dysfunction.
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Introduction
Autoimmune thyroid disease (AITD), including Hashimoto’s
thyroiditis and Graves’ disease, is one of the most common
autoimmune diseases, affecting 2–5% of the general population
[1,2,3]. Thyroid dysfunction has been associated with osteoporosis,
depression, atrial fibrillation, heart failure, metabolic syndrome, and
mortality [4,5,6,7,8,9,10,11]. High serum antibodies against the
enzyme thyroid peroxidase (TPO), which is located in the thyroid
and plays a key role in thyroid hormone synthesis, are present in 90%
of patients with Hashimoto’s thyroiditis [12,13], the most frequent
cause of hypothyroidism and goiter. Although TPO antibodies
(TPOAbs) are a useful clinical marker for the detection of early
AITD, it remains controversial if these antibodies play a causative
role in the pathogenesis of Hashimoto’s thyroiditis [14,15,16].
Interestingly, TPOAb-positive persons also have an increased
risk of developing autoimmune hyperthyroidism (Graves’ disease)
[17,18], which is caused by stimulating antibodies against the
thyroid stimulating hormone (TSH) receptor [19]. Numerous
studies have shown that Graves’ hyperthyroidism and Hashimoto’s
thyroiditis show co-inheritance [17,20,21]. Finally, thyroid auto-
immunity is the most common autoimmune disorder in women of
childbearing age, and TPOAb-positive women have an increased
risk of developing pregnancy complications such as miscarriage
and pre-term delivery [17,18,22,23,24,25,26].
The prevalence of TPOAb-positivity in the general population
ranges from 5–24%, but it is currently unknown why these people
develop TPOAbs, nor is it known why not all individuals with
thyroid autoimmunity develop clinical thyroid disease [27,28]. It is
estimated that around 70% of the susceptibility to develop thyroid
autoantibodies is due to genetic factors [29]. In this context it is
remarkable to note that little is known about the genetic factors
that determine TPOAb-positivity and the risk of AITD.
We therefore performed a genome wide association study
(GWAS) meta-analysis for TPOAbs in the general population in
18,297 individuals from 11 populations. Newly identified genetic
variants were studied in relation to subclinical and overt hypo- and
hyperthyroidism, goiter, thyroid autoimmunity during pregnancy
and thyroid cancer risk.
Results
Characteristics of the studied populations are shown in Table 1
and the Supplementary Material S1. Heritability estimates in the
family-based cohorts SardiNIA, TwinsUK and Val Borbera were,
respectively, 0.65, 0.66, and 0.54 for TPOAb-positivity, and 0.43,
0.66, and 0.30 for TPOAb levels.
Loci associated with TPOAb-positivity and TPOAb levels
See Table 1 and Supplementary Figure S1 for TPOAb
measurements and Supplementary Table S1 for genotyping
procedures. In most autoimmune diseases, both the presence
and the level of autoantibodies are relevant for the disease onset
[18,30,31]. Furthermore, different pathophysiological processes
may be involved in the initiation and severity of the autoimmune
response. We therefore performed a GWAS on TPOAb-positivity
(including 1769 TPOAb-positives and 16,528 TPOAb–negatives),
as well as a GWAS on continuous TPOAb levels (including 12,353
individuals) in stage 1. See Supplementary Figures S2 and S3 for
QQ (quantile-quantile) and Manhattan plots.
In stage 2, we followed-up 20 stage 1 SNPs (P,561026; 13
TPOAb-positivity and 10 TPOAb level SNPs, with 3 SNPs
overlapping) in 5 populations, including up to 8,990 individuals
for TPOAb-positivity (922 TPOAb-positives and 8068 TPOAb–
negatives) and 8,159 individuals for TPOAb level analyses (see
Supplementary Material S1). Results of the combined stage 1 and 2
Novel Thyroid Antibody and Disease Loci
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meta-analyses, including heterogeneity analyses, are shown in
Supplementary Tables S2 and S3. Regional association plots are
shown in Supplementary Figures S4 and S5. In the combined stage
1 and 2 meta-analyses GWAS significant associations (P,561028)
were observed near TPO (Chr 2p25; rs11675434), at ATXN2 (Chr
12q24.1; rs653178), and BACH2 (Chr 6q15; rs10944479) for
TPOAb-positivity, and near TPO (rs11675434), at MAGI3 (Chr
6q15; rs1230666), and KALRN (Chr 3q21; rs2010099) for TPOAb
levels (Table 2 and Figure 1). The TPOAb level meta-analysis P-
values for the 3 GWAS significant TPOAb-positivity loci were:
TPO-rs11675434: P=7.4610213, ATXN2-rs653178: P=1.361027,
and BACH2-rs10944479: P=2.061024.
As the 3 GWAS significant loci for TPOAb levels also showed
associations with TPOAb-positivity (TPO-rs11675434: OR, 1.21
[95% CI, 1.15–1.28)], P=1.5610216; MAGI3-rs1230666: OR,
1.23 [95% CI, 1.14–1.33], P=1.561026; KALRN-rs2010099: OR,
1.24 [95% CI, 1.12–1.37], P=7.461025), we subsequently
studied the (combined) effects of these 5 SNPs on clinical thyroid
disease. Genetic risk scores were calculated as described in the
Supplementary Material. The variance explained by these 5 SNPs
was 3.1% for TPOAb-positivity and 3.2% for TPOAb levels.
Subjects with a high genetic risk score had a 2.2 times increased
risk of TPOAb-positivity compared to subjects with a low genetic
risk score (P=8.161028) (Table 3).
Table S4 shows the stage 1 TPOAb-positivity and TPOAb level
meta-analyses results for GWAS significant SNPs reported in
previous GWAS on thyroid related phenotypes.
Associations with hypo- and hyperthyroidism
The associations between the 5 GWAS significant SNPs and the
risk of abnormal thyroid function tests are shown in Table 4.
MAGI3- rs1230666 was associated with an increased risk of overt
hypothyroidism and increased TSH levels below the Bonferroni
threshold (i.e., P= 0.05/5= 0.01). Borderline significant signals
were observed at BACH2- rs10944479 with a higher risk of
increased TSH levels as well as overt hyperthyroidism (P= 0.011
and P= 0.012), and at the KALRN-rs2010099 SNP with a lower
risk of decreased TSH levels (P= 0.010).
Furthermore, a higher genetic risk score was associated with a
higher risk of increased TSH levels (Supplementary Table S5). No
effects of the genetic risk score on the risk of overt hypothyroidism,
hyperthyroidism or decreased TSH levels were observed.
Associations with goiter
Individuals with a high genetic risk score had a 30.4% risk of
sonographically-proven goiter, compared to 35.2% in subjects
with a low score (P=6.561024) (Table 5). None of the individual
SNPs was significantly associated with goiter risk.
Thyroid autoimmunity during pregnancy
As autoimmunity significantly changes during pregnancy [25],
we additionally studied these effects in an independent pregnant
population. Pregnant women with a high genetic risk score had a
2.4 times increased risk of TPOAb-positivity compared to women
with a low score (10.3% vs 4.8%, P=0.03). These women did not
have a higher risk of increased TSH levels. However, a borderline
significant signal with a lower risk of increased TSH levels was
observed at ATXN2- rs653178 (OR, 0.54 [95% CI, 0.34–0.87],
P=0.012).
Associations with thyroid disease in independent
populations
a) Graves’ disease. As MAGI3- rs1230666 and BACH2-
rs10944479 showed promising associations (i.e., P#0.05) with
hyperthyroidism in our meta-analyses, we tested these SNPs in an
independent population of 2478 patients with Graves’ disease and
2682 controls (see Supplementary Material for further details). Both
were associated with an increased risk of Graves’ disease (MAGI3-
rs1230666: OR, 1.37 [95% CI, 1.22–1.54]; P=1.261027; BACH2-
rs10944479: OR, 1.25 [1.12–1.39]; P=6.261025).
b) Thyroid cancer. Supplementary Table S6 shows the
associations of the 5 GWAS significant SNPs with thyroid cancer.
No statistically significant associations were detected, but a
borderline significant signal with an increased risk of thyroid
cancer was observed at ATXN2- rs653178 (OR, 1.32 [95% CI,
1.02–1.70], P=0.03).
Pathway analyses
Ingenuity Pathway Analyses (IPA; Ingenuity Systems, Ca, USA)
and GRAIL analyses [32] were performed to identify potential
pathways involved in AITD, the results of which are shown in
Supplementary Tables S7 and S8, and Figure S6. The identified
top pathways involved cell death, survival, movement, and OX40
signalling.
Discussion
This is the first GWAS meta-analysis investigating the genetics
of TPOAbs in the normal population in up to 18,297 individuals
from 11 populations with replication in up to 8,990 individuals
from 5 populations. We identified 5 GWAS significant loci
associated with TPOAb-positivity and/or levels.
The most significant hit for both TPOAb-positivity and TPOAb
levels was located near the TPO gene itself. TPO is a membrane-
bound protein located on the apical membranes of the thyroid
follicular cell, catalyzing key reactions in thyroid hormone
synthesis [33]. Mutations in TPO have been found in patients
with congenital hypothyroidism [34,35]. Although TPOAbs are
Author Summary
Individuals with thyroid peroxidase antibodies (TPOAbs)
have an increased risk of autoimmune thyroid diseases
(AITD), which are common in the general population and
associated with increased cardiovascular, metabolic and
psychiatric morbidity and mortality. As the causative genes
of TPOAbs and AITD remain largely unknown, we
performed a genome-wide scan for TPOAbs in 18,297
individuals, with replication in 8,990 individuals. Significant
associations were detected with variants at TPO, ATXN2,
BACH2, MAGI3, and KALRN. Individuals carrying multiple
risk variants also had a higher risk of increased thyroid-
stimulating hormone levels (including subclinical and overt
hypothyroidism), and a decreased risk of goiter. The MAGI3
and BACH2 variants were associated with an increased risk
of hyperthyroidism, and the MAGI3 variant was also
associated with an increased risk of hypothyroidism. This
first genome-wide scan for TPOAbs identified five newly
associated loci, three of which were also associated with
clinical thyroid disease. With these markers we identified a
large subgroup in the general population with a substan-
tially increased risk of TPOAbs. These results provide
insight into why individuals with thyroid autoimmunity do
or do not eventually develop thyroid disease, and these
markers may therefore predict which individuals are
particularly at risk of developing clinical thyroid dysfunc-
tion.
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valid clinical biomarkers of AITD, they are generally considered to
be secondary to the thyroid damage inflicted by T-cells.
The FOXE1 gene has been previously associated with hypothy-
roidism [36,37] and is known to regulate transcription of TPO
[38]. In this context it is interesting to note that we did not find any
associations of the variant near TPO with hypothyroidism. Most
genes that have been associated with AITD (predominantly
Graves’ disease) by candidate gene and GWAS studies so far are
located in the HLA class I and II regions, or in genes involved in
T-cell (i.e., CTLA-4, PTPN22) or other autoimmune responses
[28,39]. Until now, the TPO gene itself had not been associated
with AITD, except in one recent candidate gene analysis in a small
cohort (n = 188) without replication [40]. A variant near TPO
(rs11694732), which is in LD with rs11675434 (r2 = 0.97 in
HapMap2), has previously been associated with TSH levels by
Gudmundsson et al [41]. However, various other GWAS on
serum TSH and FT4 levels have not found any significant
associations in or near this locus, including a recent similar sized
GWAS by Porcu et al [42].
Three of the other four loci identified here are located in or are in
linkage disequilibrium (LD) with genes previously associated with
other autoimmune diseases. Rs1230666 is located in intron 9 of
MAGI3, encoding a protein that modulates activity of AKT/PKB.
AKT/PKB is expressed in the thyroid and regulates apoptosis [43],
which seems to play an important role in the development of AITD
[44,45]. In addition, rs1230666 is in LD with rs2476601 (r2=0.70 in
HapMap2), a variant causing a R620W substitution in PTPN22.
PTPN22 is a lymphoid-specific intracellular phosphatase involved in
the T-cell receptor signaling pathway. Variations in PTPN22, and
specifically R620W, are associated with various autoimmune
disorders including type 1 diabetes, rheumatoid arthritis, systemic
lupus erythematosus and Graves’ disease [46,47,48,49]. The associ-
ations of theMAGI3 locus with TPOAb-positivity and Graves’ disease
may therefore also be explained by linkage with disease-associated
variants in PTPN22 [50]. Of note, the association signal at rs2476601
is one order weaker than that of the top variant rs1230666.
The BACH2 locus has been implicated in the susceptibility to
several autoimmune diseases, including celiac disease, type 1
diabetes, vitiligo, Crohn’s disease, and multiple sclerosis
[46,51,52,53,54]. A recent candidate gene analysis associated the
BACH2 locus with an increased risk of AITD, including
Hashimoto’s thyroiditis and Graves’ disease [55]. However, the
associations were not significant when Hashimoto’s thyroiditis and
Graves’ disease were studied separately. BACH2 is specifically
expressed in early stages of B-cell differentiation and represses
different immunoglobulin genes [56]. Interestingly, BACH2 can
bind to the co-repressor SMRT (silencing mediator of retinoid and
thyroid receptor), which may suggest a more direct effect on
thyroid hormone secretion and action as well.
Polymorphisms in ATXN2 have been associated with multiple
neurodegenerative diseases, including spinocerebellar ataxia and
Parkinson’s disease [57,58,59]. Different epidemiological studies
have associated thyroid dysfunction with cerebellar ataxia [60,61].
Furthermore, the identified SNP in ATXN2 has been previously
associated with renal function, serum urate levels and blood
pressure [62,63,64]. However, this SNP is in high LD with
rs3184504 (r2 = 0.873), a variant causing a Trp262Arg substitu-
tion of SH2B adaptor protein 3 (SH2B3). SH2B3 encodes the adaptor
protein LNK, a key negative regulator of cytokine signaling
playing a critical role in hematopoiesis. This variant is associated
with susceptibility to several autoimmune diseases, including celiac
disease, type 1 diabetes, vitiligo, and rheumatoid arthritis
[46,51,53,65], suggesting more relevance for TPOAb levels than
ATXN2. This is supported by a recent study which showed that
variants in LD with SH2B3, BACH2, and PTPN22 are associated
with TPOAb levels in patients with type 1 diabetes [66].
Whereas the above four loci are located in genes involved in the
immune response or the autoantigen, the KALRN (Kalirin) gene
encodes a multi-domain guanine nucleotide exchange factor for
GTP-binding proteins of the Rho family. The relation of KALRN
with levels of TPOAbs is unclear. This gene has recently been
found to be associated with megakaryopoiesis and platelet
formation [67], which may suggest a function in the immune
system [68]. We furthermore performed pathway analyses on the
stage 1 TPOAb-positivity and TPOAb level lead SNPs, and
identified the cell death, survival and movement pathway as an
important pathway for TPOAbs. This finding is supported by
previous studies, which show an important role for apoptosis in the
Table 2. Newly identified loci associated with TPOAb-positivity and/or serum TPOAb levels reaching genome wide significance.
Alleles
Stage 1 + 2 meta-analysis: up to 2691
cases and 24,596 controls
TPOAb-positivity SNP Chr. Position
(Build 36)
Risk Other RAFa Nearby gene OR (95% CI)b P value
rs11675434 2 1386822 T C 0.39 TPO 1.21 (1.15–1.28) 1.5610216
rs653178 12 110492139 C T 0.40 ATXN2 1.14 (1.08–1.19) 9.9610210
rs10944479 6 90937114 A G 0.16 BACH2 1.25 (1.14–1.37) 4.061028
Alleles Stage 1 + 2 meta-analysis: up to 20,512
subjects
TPOAb levels SNP Chr. Position
(Build 36)
Risk Other RAFa Nearby gene b (SE)c P value
rs11675434 2 1386822 T C 0.39 TPO 0.0202 (0.0046) 7.4610213
rs1230666 1 113974933 A G 0.16 MAGI3 0.0269 (0.0064) 1.861028
rs2010099 3 125782947 C T 0.91 KALRN 0.0240 (0.0076) 3.161028
Chr., chromosome
aRisk allele frequency: Weighted mean frequency of the risk allele across all included cohorts.
bAdjusted for age and gender
cExpressed in sd of natural logarithm transformed serum TPOAb level, adjusted for age and gender
doi:10.1371/journal.pgen.1004123.t002
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development of AITD [44,45]. Another top pathway involved was
the OX40 signalling pathway, and it is of interest to note that
OX40 is a T-cell activator promoting the survival of CD4+ T-cells
at sites of inflammation [69].
Our results have potential clinical relevance for several reasons.
Genetic risk scores based on these novel common (risk allele
frequencies: 9–40%) TPOAb-associated SNPs enabled us to iden-
tify a large subgroup in the general population with a two-fold
Figure 1. Genome wide association studies meta-analyses: Loci associated with TPOAb-positivity (a–c) and TPOAb levels (d–f) on a
genome-wide level of significance. Regional association plots of the genome-wide significant loci associated with TPOAb positivity (a–c) and
TPOAb levels (d–f). The y-axis on the left indicates the – log10 P value for the association with TPOAb –positivity (a–c) or TPOAb levels (d–f). SNPs are
plotted on the x-axis according to their chromosomal position against the association with the phenotype on the y-axis. The most significant stage 1
SNP is indicated in purple. The combined stage 1 and 2 result of this SNP is indicated in yellow. The SNPs surrounding the most significant SNP are
color-coded to reflect their LD with this SNP. Symbols reflect functional genomic annotation, as indicated in the legend. The blue y-axes on the right
of each plot indicate the estimated recombination rates (based on HapMap Phase II); the bottom of each panel shows the respective annotated
genes at the locus and their transcriptional direction. Mb, megabases.
doi:10.1371/journal.pgen.1004123.g001
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increased risk of TPOAb-positivity (10.4% vs 5.4%). These
individuals also have a higher risk of increased TSH levels and a
lower risk of goiter, suggesting an advanced stage of destruction of
the thyroid due to autoimmune processes. Furthermore, pregnant
women with high genetic risk scores had a 2.4 times increased risk
of TPOAb-positivity during pregnancy. In this context it is
interesting to note that TPOAb-positive pregnant women have an
increased risk of miscarriages and preterm births independent of
thyroid function [70].
Associations with thyroid disease were also found on an
individual SNP level. The MAGI3 SNP was associated with a
substantially increased risk of hypothyroidism, and the BACH2
SNP showed a borderline significant association (P=0.011) with a
higher risk of increased TSH levels, which includes subjects with
subclinical and overt hypothyroidism. Furthermore, both loci were
significantly associated with an increased risk of Graves’ hyper-
thyroidism in an independent population. To predict which
patients with first or second degree relatives with documented
Hashimoto’s or Graves’ disease will develop clinical thyroid
disease, a clinical algorithm has been developed (i.e., the THEA
score) [18]. Future studies should analyze if these genetic markers
increase the sensitivity of the THEA score. Graves’ hyperthyroid-
ism and Hashimoto’s thyroiditis co-segregate in families and
subjects with TPOAbs have an increased risk of both diseases
[17,18,20,21,22,26]. The current study provides insight into this
phenomenon by showing that specific loci associated with
TPOAbs and (subclinical) hypothyroidism, i.e. MAGI3 and
BACH2, are also associated with Graves’ hyperthyroidism in an
independent case-control study.
The prevalence of TPOAb-positivity in the general population
is high (5–24%), but it is currently unknown why part of the
individuals with thyroid autoimmunity develop clinical thyroid
disease whereas others do not [27,28]. In this context it is
interesting to note that the TPOAb-associated SNPs located in
TPO and ATXN2 were not associated with clinical thyroid disease.
This suggests that the TPOAbs in these individuals may be of less
clinical relevance, providing insight into why TPOAb-positive
individuals do or do not eventually develop clinical thyroid disease.
Our study has some limitations. The validity of the results is
restricted to individuals from populations of European ancestry.
Future GWASs in populations from non-European descent will be
required to determine to which extent our results can be
generalized to other ethnic groups. Secondly, we did not perform
conditional analyses to further identify secondary association
signals within the identified loci, nor did we perform functional
studies for the identified variants. Further research is therefore
needed to unravel the exact biological mechanism behind the
observed associations. The fact that various TPOAb assays were
used across the participating cohorts could lead to bias. We
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Table 3. Genetic risk score and the risk of TPOAb-positivity.
GRS Quartile
% TPOAb-positivity
(N cases/total) OR (95% CI)a P value
1 (reference) 5.4% (89/1637) - -
2 7.0% (114/1637) 1.29 (0.98–1.69) 0.07
3 9.0% (152/1695) 1.64 (1.26–2.13) 1.361024
4 10.4% (158/1523) 2.18 (1.68–2.81) 8.161028
GRS, genetic risk score (based on rs11675434, rs653178, rs10944479, rs1230666,
rs2010099).
aAdjusted for age and gender
doi:10.1371/journal.pgen.1004123.t003
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therefore used TPOAb-positivity cut-off values as provided by the
respective assay manufacturer, instead of using one fixed cut-off
value. This is also of clinical importance as in clinical practice most
institutions rely on the TPOAb-positivity cut-off as provided by
the assay manufacturer. Furthermore, we did not detect hetero-
geneity in our results, supporting the fact that results obtained with
different assays can be combined across cohorts using the z-score
based meta-analysis. Finally, as AITD coincides with other
autoimmune diseases, our results could be driven by indirect
associations with other autoimmune diseases. However, AITD is
the most common autoimmune disease in the general population.
We furthermore show that carriage of multiple risk alleles is
associated with an increased risk of thyroid dysfunction, which
underlines the clinical importance of our findings.
In conclusion, this first GWAS for TPOAbs identified five newly
associated loci, three of which were also associated with clinical
thyroid disease. Furthermore, we show that carriage of multiple
risk variants is not only associated with a substantial increased risk
of TPOAb-positivity, but also with a higher risk of increased TSH
levels (including subclinical and overt hypothyroidism) and a lower
risk of goiter. These genetic markers not only help to identify large
groups in the general population with an increased risk of TPOAb-
positivity, but may also predict which TPOAb-positive persons are
particularly at risk of developing clinical thyroid disease.
Materials and Methods
Study cohorts
For the TPOAb GWAS stage 1 and 2 analyses, and the
hypothyroidism, hyperthyroidism and goiter analyses, individuals
were recruited from 16 independent community-based and family
studies. For the Graves’ disease analyses, cases were recruited from
the United Kingdom Graves’ disease cohort and controls from the
British 1958 Birth Cohort. Thyroid cancer cases and controls were
recruited from the Nijmegen and Ohio thyroid cancer cohorts. A
detailed description of the original cohorts contributing samples is
provided in Table 1 and in the Supplementary Material. All
participants provided written informed consent and protocols were
approved by the institutional review boards or research ethics
committees at the respective institutions, and conducted according
to the Declaration of Helsinki.
Phenotype definitions
Serum TPOAb levels were determined with a range of assays.
TPOAb-positives were defined as subjects with TPOAb levels
above the assay-specific TPOAb-positivity cut-off, as defined by
the manufacturer (Table 1). Serum TSH and free thyroxine (FT4)
levels were determined using a range of assays (Table 1). Assay-
specific TSH and FT4 reference ranges were used, as provided by
the manufacturer (Table 1). Overt hypothyroidism was defined as
a high TSH (i.e., a TSH level above the TSH reference range) and
a low FT4. Increased TSH was defined as a high TSH, including
persons with overt hypothyroidism or subclinical hypothyroidism
(i.e., high TSH with a normal FT4). Overt hyperthyroidism was
defined as a low TSH and a high FT4. Decreased TSH was
defined as a low TSH, including persons with subclinical or overt
hyperthyroidism.
The diagnosis of goiter is described in the Supplementary
Material, and the diagnosis of Graves’ disease and thyroid cancer
in the respective cohorts have been described previously [41].
Genotyping
Samples were genotyped with a range of GWAS genotyping
arrays (Supplementary Table S1). Sample and SNP quality control
procedures were undertaken within each study. For each GWAS,
over 2.5 million SNPs were imputed using CEU samples from
Phase 2 of the International HapMap project (www.hapmap.org).
Genotyping procedures in the stage 2, Graves’ disease and
thyroid cancer populations are described in the Supplementary
Material.
Association analyses
The heritabilities of TPOAb-positivity and serum TPOAb levels
were estimated, as described in the Supplementary Material.
In stage 1, we performed a GWAS on TPOAb-positivity as well
as a GWAS on continuous TPOAb levels. Persons taking thyroid
medication were excluded. Each SNP was tested for association
with TPOAb-positivity using logistic regression analyses, adjusting
for age and sex. For cohorts with family structure, we approximated
the probability of being affected with a linear mixed model adjusting
for age and sex. The produced model was used to predict the
expected proportion of ‘‘risk’’ (effective) alleles in cases and controls,
hence giving the means to estimate odds ratios. Only unrelated
individuals were considered for the SardiNIA cohort. For the
GWAS of continuous TPOAb levels, samples with a TPOAb level
lower than the minimum TPOAb assay detection limit (Table 1)
were excluded. TPOAb levels were natural log-transformed,
and sex-specific, age adjusted standardized residuals were calcu-
lated. Each SNP was tested for association with these TPOAb
level residuals using linear regression analyses (additive model),
Table 5. Newly identified TPOAb associated loci, genetic risk scores and the risk of goiter.
Individual SNPs (2205 goiter cases/4532 controls) Genetic risk scores
Nearby gene SNP
Risk
allele
Other
allele OR (95% CI)a P value GRS Quartile
% Goiter
(N cases/total) OR (95% CI)a P value
TPO rs11675434 T C 0.95 (0.88–1.02) 0.17 1 (reference) 35.2% (588/1669) - -
ATXN2 rs653178 C T 0.95 (0.88–1.03) 0.22 2 33.7% (570/1691) 0.92 (0.79–1.06) 0.21
BACH2 rs10944479 A G 0.94 (0.85–1.05) 0.28 3 31.6% (530/1675) 0.84 (0.72–0.98) 0.03
MAGI3 rs1230666 A G 0.90 (0.81–1.00) 0.05 4 30.4% (517/1702) 0.77 (0.66–0.89) 6.561024
KALRN rs2010099 C T 0.93 (0.81–1.05) 0.23
GRS, genetic risk score (based on rs11675434, rs653178, rs10944479, rs1230666, rs2010099).
aAdjusted for age, gender, and body surface area.
ATXN2-rs653178 is in high LD with SH2B3-rs3184504.
MAGI3-rs1230666 is in high LD with PTPN22-rs24756601.
doi:10.1371/journal.pgen.1004123.t005
Novel Thyroid Antibody and Disease Loci
PLOS Genetics | www.plosgenetics.org 10 February 2014 | Volume 10 | Issue 2 | e1004123
correcting for relatedness in studies with family structure. See
Supplementary Table S1 for the software used for these analyses.
Before meta-analysis, SNPs with a minor allele frequency (MAF)
,1% or a low imputation quality were excluded (Supplementary
Material), after which the results of each GWAS were combined in
a population size weighted z-score based meta-analysis using
METAL [71]. Genomic control was applied to individual studies if
l.1.0.
In stage 2, we followed-up stage 1 GWAS significant SNPs, as
well as promising SNPs not reaching GWAS significance, in an
attempt to reach GWAS significant associations by increasing
sample size (Supplementary Material). Results from stage 1 and 2
were combined in a population size weighted z-score based meta-
analysis using METAL [71]. A z-score based meta-analysis was
used to reduce bias that might be induced by different assays. As
this method does not provide betas, and we wanted to provide a
rough estimate of the actual effect sizes for convenience, we
calculated betas using the fixed effects (inverse variance based)
meta-analysis method. Heterogeneity was tested, applying bonfer-
roni based P-value thresholds of P=0.004 for the TPOAb-
positivity analyses and P=0.005 for the TPOAb level analyses.
All studies assessed and, if present, corrected for population
stratification using principal-component analysis (PCA) and/or
multidimensional-scaling (MDS), with the exception of SardiNIA
and ValBorbera where the high isolation substantiates a lack of
stratification (Table S1) [72,73]. Lambda values were all ,1,
indicating that population stratification was overall properly
accounted for (Table S1). To fully remove residual effects, we
applied genomic correction to studies were lambda was .1. The
final meta-analyses reported a lambda of 1.01 for both the
TPOAb-positivity and the TPOAb level GWAS, thus no genomic
correction was applied.
The variances explained by the GWAS significant SNPs were
calculated. We subsequently studied the individual as well as the
combined effects of the GWAS significant SNPs on the risk of
clinical thyroid disease, as specified in the Supplementary
Material. In short, to study combined effects, a genetic risk score
was calculated for every person as the weighted sum of TPOAb
risk alleles. The associations between the individual SNPs, genetic
risk scores and the risk of abnormal thyroid function tests were
studied using logistic regression analyses. Logistic regression
analyses were used to study the associations with goiter, Graves’
disease and thyroid cancer (Supplementary Material). The results
of each study were combined in a population size weighted z-score
based meta-analysis using METAL [71].
Various bioinformatic tools were searched for evidence for
functional relevance of the GWAS significant SNPs and pathway
analyses were performed on the Stage 1 lead SNPs (see
Supplementary Material).
Supporting Information
Figure S1 TPOAb level distributions in persons with detectable
TPOAb levels in stage 1 and 2 populations.
(PPTX)
Figure S2 Quantile-quantile (QQ) plots for the TPOAb-
positivity and TPOAb level stage 1 meta-analyses.
(PPTX)
Figure S3 Manhattan plots for stage 1 meta-analyses for
TPOAb-positivity (a) and TPOAb levels (b). SNPs are plotted on
the x-axis according to their chromosomal position against
TPOAb-positivity (a) or TPOAb levels (b) (shown as – log10 P
value) on the y-axis. The horizontal grey line indicates the
threshold for genome-wide statistical significance (P,561028).
Genome-wide significant associations were observed near TPO
(Chr 2p25; P=1.5610212), at ATXN2 (Chr 12q24.1;
P=1.661029) and near HCP5 (Chr 6p21.3; P=4.161028) for
TPOAb-positivity, and near TPO (Chr 2p25; P=5.4610213) and
at ATXN2 (Chr 12q24.1; P=1.161028) for TPOAb levels.
(PPTX)
Figure S4 Regional association plots of stage 1 lead loci for
TPOAb-positivity (panels a-m). The y-axis on the left indicates the
– log10 P value for the association with TPOAb –positivity. SNPs
are plotted on the x-axis according to their chromosomal position.
The most significant stage 1 SNP is indicated in purple. The
combined stage 1 and 2 result of this SNP is indicated in yellow.
The SNPs surrounding the most significant SNP are color-coded
to reflect their LD with this SNP. Symbols reflect functional
genomic annotation, as indicated in the legend. The blue y-axes
on the right of each plot indicate the estimated recombination
rates (based on HapMap Phase II); the bottom of each panel shows
the respective annotated genes at the locus and their transcrip-
tional direction. Mb, megabases.
(PPTX)
Figure S5 Regional association plots of stage 1 lead loci for
TPOAb levels (panels a-j). The y-axis on the left indicates the –
log10 P value for the association with TPOAb levels. SNPs are
plotted on the x-axis according to their chromosomal position.
The most significant stage 1 SNP is indicated in purple. The
combined stage 1 and 2 result of this SNP is indicated in yellow.
The SNPs surrounding the most significant SNP are color-coded
to reflect their LD with this SNP. Symbols reflect functional
genomic annotation, as indicated in the legend. The blue y-axes
on the right of each plot indicate the estimated recombination
rates (based on HapMap Phase II); the bottom of each panel shows
the respective annotated genes at the locus and their transcrip-
tional direction. Mb, megabases.
(PPTX)
Figure S6 GRAIL results for the stage 1 TPOAb-positivity and
TPOAb level lead SNPs. GRAIL circle plot of locus connectivity
where each locus is plotted in a circle, where significant
connections (P,0.05) based on PubMed abstracts are drawn
spanning the circle. Analyses were based on the 20 stage 1
TPOAb-positivity and TPOAb level lead SNPs.
(PPTX)
Table S1 Study sample genotyping, quality control and
association analyses for stage 1 populations.
(DOCX)
Table S2 Associations of stage 1 lead SNPs with TPOAb-
positivity in stage 1 and 2.
(DOCX)
Table S3 Associations of stage 1 lead SNPs with serum TPOAb
levels in stage 1 and 2.
(DOCX)
Table S4 Stage 1 TPOAb-positivity and TPOAb level meta-
analyses results for GWAS significant SNPs reported in previous
GWAS on thyroid related phenotypes.
(XLSX)
Table S5 Genetic risk score and the risk of increased TSH levels.
(DOCX)
Table S6 Newly identified TPOAb associated loci and the risk of
thyroid cancer.
(DOCX)
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Table S7 Top IPA associated networks for the Stage 1 TPOAb-
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